Jan 11 (Reuters) - Novartis has backed away from its pursuit of Cytokinetics, the Wall Street Journal reported on Thursday, citing sources. (Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
98.9 CHF | -0.20% | +1.86% | +16.53% |
Jul. 15 | Brace for a flurry of speeches from Fed officials | |
Jul. 15 | European companies cut jobs as economy sputters | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
98.9 CHF | -0.20% | +1.86% | 226B | ||
56.76 USD | -1.10% | +3.46% | 6.67B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.53% | 226B | |
+61.53% | 856B | |
+38.95% | 631B | |
-3.66% | 359B | |
+15.06% | 325B | |
+9.18% | 297B | |
+5.89% | 234B | |
+15.67% | 177B | |
+2.47% | 165B | |
+2.41% | 126B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis drops pursuit of Cytokinetics - WSJ